Summary
C2N Diagnostics LLC (C2N Diagnostics) is a protein diagnostic and therapeutic discovery company that offers progressive neurodegeneration solutions. The company develops tools and assays for clinical drug development, preclinical drug discovery and early detection and assessment of neurodegenerative disorders. It offers products such as SILK-Ab and SISAQ-Ab assays. C2N Diagnostics' products are used for the measurement of kinetics, or in vivo metabolism, and absolute quantitation of brain derived proteins. The company also develops products used in the treatment of Huntington’s disease, Parkinson's disease, brain injury, amyotrophic lateral sclerosis and schizophrenia, among others. C2N Diagnostics is headquartered in St. Louis, Missouri, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook